Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697395 · ClinicalTrials.gov registry record · Phase 2
Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant
A Phase 2 study of Chronic Rejection of Lung Transplant, sponsored by University of Virginia.
- Active
- Registry status
- Phase 2
- Development phase
- 1,200
- Enrollment target
- 1
- Study location
NCT03697395: Active Phase 2 study of Chronic Rejection of Lung Transplant, sponsored by University of Virginia.
NCT03697395 is a Phase 2 study of Chronic Rejection of Lung Transplant that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 1,200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (802% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03697395, a Phase 2 study of Chronic Rejection of Lung Transplant, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue in patients after lung transplant. This study is a registry-forming study with concurrent tissue banking from surveillance bronchoscopy in addition to extra tissue sampling of blood and urine. Patients will be characterized by usual clinical phenotyping and the latest imaging methods so that diseased condition underlying CLAD can be better understood.
Primary Outcome
Completion of surveillance bronchoscopy and other tissue collection at planned surveillance (24 months after the date of lung transplant surgery)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Lung transplant recipient without MRI imaging
- DRUG Lung transplant recipient with MRI imaging
Study Locations (1)
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2038-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03697395 still lists
NCT03697395 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (802% higher).
The record links to 1 condition, with Chronic Rejection of Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Lung transplant recipient without MRI imaging is the first listed.
NCT03697395 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03697395 about?
NCT03697395 is a clinical study titled "Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant". Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue in patients after lung transplant. This study is a registry-forming study with concurrent tissue banking from surveillance bronchoscopy in addition to extra tissue sampling of blood and urine. Patients will be charac...
What is the current status of trial NCT03697395?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,200 participants. The study started on 2019-04-01. Estimated completion is 2038-12-31.
What conditions does trial NCT03697395 study?
This clinical trial studies the following conditions: Chronic Rejection of Lung Transplant.
What interventions are being tested in trial NCT03697395?
The interventions under investigation include: Lung transplant recipient without MRI imaging (DIAGNOSTIC_TEST), Lung transplant recipient with MRI imaging (DRUG).
Who is sponsoring clinical trial NCT03697395?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03697395 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rejection of Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03697395's enrollment target sits among peer trials
1,200 17th of 2000 higher than 1,983 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI